SCHEMBL10134952

SCHEMBL10134952

CN(C)CCCNc1nc2cc(C#N)ccc2c2sccc12

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 11/20 0.58
CSNK2A2 P19784 2/20 0.52
CSNK2B P67870 2/20 0.52
FLT3 P36888 4/20 0.43
ALDH1A1 P00352 2/20 0.41
PKM P14618 1/20 0.41
TOP2A P11388 1/20 0.41
MAPK1 P28482 1/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
SLC2A1 P11166 1/20 0.39
APOBEC3A P31941 1/20 0.39
RAD52 P43351 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
EGLN2 Q96KS0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10132891 0.94 CSNK2A1 (0.66) CSNK2A1CSNK2A2CSNK2BFLT3TOP2A
SCHEMBL10135002 0.86 CSNK2A1 (0.52) CSNK2A1CSNK2A2CSNK2B
SCHEMBL10134902 0.85 CSNK2A1 (0.65) CSNK2A1CSNK2A2CSNK2B
SCHEMBL10134876 0.85 CSNK2A1 (0.54) CSNK2A1CSNK2A2CSNK2BFLT3TOP2A
SCHEMBL10135017 0.84 CSNK2A1 (0.53) CSNK2A1CSNK2A2CSNK2B
SCHEMBL13688058 0.84 CSNK2A1 (0.61) CSNK2A1CSNK2A2CSNK2BFLT3ALDH1A1
SCHEMBL10135014 0.83 CSNK2A1 (0.47) CSNK2A1CSNK2A2CSNK2B
SCHEMBL10134954 0.81 CSNK2A1 (0.40) CSNK2A1
SCHEMBL10135018 0.81 CSNK2A1 (0.47) CSNK2A1CSNK2A2CSNK2BEGLN2
SCHEMBL10134913 0.79 CSNK2A1 (0.48) CSNK2A1CSNK2A2CSNK2BALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.